ADCY4 Antibody

What is ADCY4 and why is it relevant to cancer research?

ADCY4 is a protein-coding gene that encodes an adenylate cyclase enzyme involved in purine metabolism and inflammatory pathways. Recent studies have identified ADCY4 as a potential biomarker in several cancer types, particularly in relation to metastasis and prognosis. ADCY4 has been associated with diseases such as adenoma, thyroid adenoma, and is functionally linked to perturbation of adenylate cyclase activity . In cancer research, ADCY4 has gained attention because it appears to mediate poor prognosis through energy metabolism-related pathways, particularly in small cell lung cancer (SCLC) brain metastasis .

What are the recommended experimental controls when validating ADCY4 antibodies?

When validating ADCY4 antibodies, researchers should implement several controls:

• Positive tissue controls: Use samples known to express ADCY4 (e.g., lung cancer cell lines like NCI-H209 and NCI-H526 that show elevated ADCY4 expression)

• Negative controls: Include tissues or cell lines with minimal ADCY4 expression

• Peptide competition assays: Pre-incubate the antibody with the immunizing peptide to confirm specificity

• Knockout/knockdown validation: Compare antibody staining between wild-type cells and those with ADCY4 knockdown or knockout

• Cross-reactivity testing: Validate against related adenylyl cyclase family members (ADCY1, ADCY2, ADCY5) to confirm specificity

How should ADCY4 protein expression be quantified in immunohistochemistry?

ADCY4 protein expression in immunohistochemistry should be evaluated semi-quantitatively using a combined scoring system that accounts for both staining intensity and percentage of positive cells. According to established protocols:

• Area score (percentage of positive-stained cells):

  • 0 = 0-10%

  • 1 = 10-25%

  • 2 = 25-50%

  • 3 = 50-75%

  • 4 = 75-100%

• Intensity score:

  • 0 = negative

  • 1 = weak

  • 2 = moderate

  • 3 = strong

The final immunostaining score is calculated as the average of scores determined by two independent pathologists. Samples with final scores greater than 2 are considered to have high expression, while those with scores of 2 or less are classified as having low expression .

Which detection methods are most effective for ADCY4 antibody-based assays?

For optimal detection of ADCY4 using antibody-based assays, researchers should consider:

• Immunohistochemistry (IHC): Particularly effective for analyzing ADCY4 expression patterns in tissue samples and determining subcellular localization

• PCR: Useful for quantifying ADCY4 mRNA expression, as demonstrated in SCLC cell lines NCI-H209 and NCI-H526

• Western blotting: Effective for protein expression analysis and evaluating antibody specificity

• Immunofluorescence: Valuable for determining subcellular localization (as shown with related adenylyl cyclase family members)

• ELISA: Useful for quantitative detection in serum or cell lysates

The choice of method should align with research objectives, with PCR typically being most sensitive for expression analysis, while IHC provides valuable spatial information about protein distribution within tissues.

How can researchers optimize ADCY4 antibody specificity for closely related adenylyl cyclase family members?

Optimizing ADCY4 antibody specificity against related family members (ADCY1, ADCY2, ADCY5) requires:

• Epitope selection: Choose antibodies targeting unique regions of ADCY4 not conserved in other family members

• Validation using multiple antibody clones: Test several antibodies targeting different epitopes

• Pre-absorption controls: Conduct cross-reactivity testing with recombinant proteins of each family member

• Sequence alignment analysis: Identify regions of low homology between ADCY family members as potential specific epitopes

• Knockout validation: Verify specificity using ADCY4-knockout tissues/cells alongside wild-type controls

For advanced applications, consider using comparative expression analysis between ADCY2, ADCY4, and ADCY5, as these have been shown to exhibit co-expression patterns in certain cancer types .

What fixation and antigen retrieval protocols yield optimal results for ADCY4 immunohistochemistry?

For optimal ADCY4 immunohistochemistry results:

• Fixation:

  • Use 10% neutral-buffered formalin for 24-48 hours

  • Alternatively, use fresh-frozen tissues for applications requiring higher sensitivity

• Antigen retrieval:

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0) for 20 minutes

  • For challenging samples, consider using EDTA buffer (pH 9.0)

• Blocking:

  • Block with 5% normal serum from the species of the secondary antibody

  • Include 0.3% hydrogen peroxide to block endogenous peroxidase activity

• Antibody incubation:

  • Optimize primary antibody dilution (typically 1:100 to 1:500)

  • Incubate overnight at 4°C for maximal sensitivity

• Detection:

  • Use polymer-based detection systems for higher sensitivity and lower background

  • Consider tyramide signal amplification for low-abundance targets

How does ADCY4 expression correlate with cancer prognosis across different tumor types?

ADCY4 expression shows distinct prognostic correlations across different cancer types:

• Small Cell Lung Cancer (SCLC):

  • Increased ADCY4 expression correlates with brain metastasis and poor prognosis

  • ADCY4 mediates poor prognosis through energy metabolism-related pathways

• Lung Squamous Cell Carcinoma (LUSC):

  • Low expression of ADCY4 predicts worse survival outcomes

  • Acts as a potential tumor suppressor in this context

• Bladder Urothelial Carcinoma (BLCA):

  • ADCY4 exhibits a co-expression pattern with ADCY2 and ADCY5

  • This pattern correlates with cancer occurrence and prognosis

• Breast Cancer:

  • ADCY4 is significantly down-regulated

  • Downregulation is related to promoter hypermethylation

These contrasting roles across cancer types highlight the context-dependent nature of ADCY4 function, suggesting that researchers should carefully interpret expression data within the specific tumor microenvironment being studied.

What is the relationship between ADCY4 expression and immune cell infiltration in cancer?

Research has identified significant relationships between ADCY4 expression and immune cell infiltration patterns:

• In SCLC patients with brain metastasis, ADCY4 expression correlates with increased infiltration of:

  • Memory B cells

  • Regulatory T cells (Tregs)

  • Activated NK cells

  • M0 macrophages

  • Activated dendritic cells

• ADCY4 expression changes significantly after anti-PD1 antibody treatment in SCLC cell lines:

  • Treatment decreases ADCY4 expression

  • This correlates with changes in energy metabolism factors

• Potential applications for immunotherapy selection:

  • ADCY4 expression may help identify patients who could benefit from immunotherapy

  • Related family member ADCY2 has shown potential to predict immunotherapy efficacy in bladder cancer

This connection between ADCY4 and immune cell infiltration suggests that ADCY4 antibodies could be valuable tools for investigating immune-related mechanisms in cancer progression and response to immunotherapy.

How can ADCY4 be targeted in combination with checkpoint inhibitors?

Combining ADCY4-targeting strategies with checkpoint inhibitors:

• Rationale based on experimental evidence:

  • Anti-PD1 antibody treatment significantly decreases ADCY4 expression in SCLC cell lines

  • This correlates with decreased cell viability and increased apoptotic markers (decreased BCL-2, increased BAX, CASP3, and CASP9)

• Potential combination approaches:

  • Sequential therapy: ADCY4 inhibition followed by checkpoint blockade

  • Concurrent therapy: Simultaneous targeting of ADCY4 and immune checkpoint pathways

  • ADCY4 antibody-drug conjugates combined with checkpoint inhibitors

• Monitoring parameters in combination studies:

  • ADCY4 expression levels before and after treatment

  • Energy metabolism markers (E-CAD, N-CAD, VIM, FN1)

  • Immune cell infiltration patterns (memory B cells, Tregs, activated NK cells)

  • Apoptotic markers (BCL-2, BAX, CASP3, CASP9)

• Predictive biomarkers for combination therapy:

  • Baseline ADCY4 expression levels

  • Immune infiltration profiles

  • Energy metabolism pathway activation status

How do post-translational modifications affect ADCY4 antibody binding affinity and specificity?

Post-translational modifications (PTMs) of ADCY4 can significantly impact antibody binding:

• Common PTMs affecting ADCY4:

  • Phosphorylation at serine/threonine residues

  • Ubiquitination regulating protein degradation

  • Glycosylation affecting protein folding and stability

• Antibody selection considerations:

  • Determine whether the antibody recognizes modified or unmodified forms

  • For phospho-specific detection, use antibodies raised against phosphorylated peptides

  • Consider native conformation requirements for optimal binding

• Validation approaches for PTM-specific detection:

  • Treatment with phosphatases or glycosidases to remove specific modifications

  • Use of inhibitors to induce or prevent specific modifications

  • Parallel analysis with PTM-specific and total protein antibodies

• Experimental design implications:

  • Sample preparation methods may preserve or destroy specific PTMs

  • Timing of sample collection may capture different modification states

  • Consider cell signaling context when interpreting antibody binding results

What are the challenges in developing ADCY4 antibody-drug conjugates (ADCs) for targeted cancer therapy?

Developing ADCY4-targeted ADCs presents several unique challenges:

• Target validation considerations:

  • Confirm ADCY4 internalization rates upon antibody binding

  • Verify expression levels across tumor vs. normal tissues

  • Assess homogeneity of expression within tumors

• Antibody selection parameters:

  • Optimize binding affinity (ideal range: 0.1-1.0 nM)

  • Select antibodies with high internalization efficiency

  • Consider antibody fragments (Fab, scFvs) for better tumor penetration

• Linker-payload design issues:

  • Cleavable vs. non-cleavable linkers affect drug release mechanisms

  • Payload selection based on ADCY4 expression levels and internalization rates

  • Drug-to-antibody ratio optimization for efficacy/toxicity balance

• Analytical methods for ADC characterization:

  • Total antibody concentration (TAb) via ligand binding assay or hybrid LC-MS/MS

  • Conjugated drug (ADC) quantification

  • Free payload assessment via LC-MS/MS

  • Metabolite profiling to identify breakdown products

• Addressing potential resistance mechanisms:

  • ADCY4 downregulation after treatment

  • Changes in internalization or trafficking

  • Alterations in energy metabolism pathways

How can researchers resolve contradictory findings regarding ADCY4's role in different cancer types?

Addressing contradictory findings about ADCY4 in cancer requires:

• Context-specific analysis:

  • ADCY4 shows different prognostic implications across cancer types:

    • Increased expression correlates with poor outcomes in SCLC

    • Low expression predicts worse survival in LUSC

  • Design experiments that account for specific tissue microenvironments

• Methodological standardization:

  • Use consistent antibody clones and detection methods

  • Standardize scoring systems for expression evaluation

  • Employ multiple detection techniques (IHC, PCR, Western blot) for confirmation

• Mechanistic investigations:

  • Explore tissue-specific binding partners and signaling pathways

  • Investigate epigenetic regulation (e.g., promoter hypermethylation)

  • Examine subcellular localization differences that may explain functional variations

• Integration with multi-omics data:

  • Correlate ADCY4 protein expression with transcriptomic profiles

  • Incorporate mutation and copy number variation analysis

  • Consider metabolomic changes related to adenylate cyclase activity

• Functional validation:

  • Perform knockout/knockin studies in multiple cell types

  • Use pathway inhibitors to probe context-dependent mechanisms

  • Develop in vivo models that recapitulate tissue-specific microenvironments

How can ADCY4 antibodies be integrated into multiplexed imaging platforms for spatial analysis of tumor microenvironments?

Integrating ADCY4 antibodies into multiplexed imaging workflows:

• Platform selection considerations:

  • Cyclic immunofluorescence (CycIF) for sequential staining with multiple antibodies

  • Mass cytometry imaging (IMC) for highly multiplexed metal-tagged antibody detection

  • Digital spatial profiling (DSP) for quantitative spatial analysis

• Panel design strategies:

  • Include ADCY4 alongside immune cell markers (CD8, CD4, FoxP3, CD68)

  • Add energy metabolism markers (E-CAD, N-CAD, VIM, FN1)

  • Incorporate apoptotic markers (BCL-2, BAX, CASP3, CASP9)

• Validation requirements:

  • Test for antibody cross-reactivity in multiplexed panels

  • Optimize signal-to-noise ratios for each detection channel

  • Include appropriate controls for background subtraction

• Data analysis approaches:

  • Develop spatial correlation metrics between ADCY4 and immune cells

  • Apply neighborhood analysis to identify cellular interaction patterns

  • Implement machine learning algorithms for pattern recognition

• Translational applications:

  • Identify spatial biomarkers predictive of immunotherapy response

  • Map ADCY4 expression relative to infiltrating immune populations

  • Correlate spatial patterns with patient outcomes

What are the optimal approaches for studying ADCY4 protein-protein interactions in cancer cells?

For investigating ADCY4 protein interactions:

• Proximity-based methods:

  • Proximity ligation assay (PLA) for in situ visualization of interactions

  • BioID or APEX2 proximity labeling to identify interaction networks

  • FRET/BRET approaches for real-time interaction monitoring

• Affinity-based approaches:

  • Co-immunoprecipitation with ADCY4-specific antibodies

  • Tandem affinity purification for higher stringency

  • Crosslinking mass spectrometry for transient interactions

• Functional validation strategies:

  • Mutation of key binding domains to disrupt specific interactions

  • Competitive peptide inhibitors targeting interaction interfaces

  • CRISPR-based genetic screens to identify essential partners

• Computational prediction tools:

  • Structural modeling of ADCY4 and potential partners

  • Protein-protein docking simulations

  • Network analysis of known adenylyl cyclase interaction partners

• Context-specific considerations:

  • Compare interaction profiles across different cancer types

  • Assess how post-translational modifications affect interactions

  • Examine changes in interactions following therapeutic interventions

How does ADCY4 subcellular localization influence its function and antibody detection efficacy?

ADCY4 subcellular localization has important implications:

• Known localization patterns:

  • Primarily membrane-associated as part of the adenylyl cyclase family

  • Potential cytoplasmic distribution when truncated or mutated (as observed with ADCY1)

  • Possible nuclear translocation under specific conditions

• Antibody selection for localization studies:

  • Choose antibodies targeting epitopes accessible in native conformation

  • Consider membrane permeabilization requirements for intracellular epitopes

  • Validate antibodies using subcellular fractionation techniques

• Technical approaches for localization studies:

  • High-resolution confocal microscopy with marker co-localization

  • Super-resolution microscopy for detailed subcellular distribution

  • Live-cell imaging with fluorescently tagged ADCY4 for dynamic studies

• Functional correlations:

  • Membrane localization required for canonical adenylyl cyclase activity

  • Cytoplasmic localization may indicate inactive or alternative functions

  • Trafficking between compartments may regulate signaling dynamics

• Disease-specific considerations:

  • Altered localization patterns in cancer cells compared to normal tissues

  • Potential mislocalization as a mechanism of dysfunction

  • Therapeutic implications of targeting specific subcellular pools

What are the best practices for validating ADCY4 antibodies for specific research applications?

Comprehensive ADCY4 antibody validation should include:

• Specificity testing:

  • Western blot showing single band at expected molecular weight

  • Testing in ADCY4 knockout/knockdown models

  • Peptide competition assays

  • Cross-reactivity testing against other adenylyl cyclase family members

• Application-specific validation:

  • For IHC: Test multiple fixation and antigen retrieval protocols

  • For flow cytometry: Optimize permeabilization conditions

  • For ChIP applications: Verify DNA-binding capacity

  • For IP applications: Confirm pull-down efficiency

• Reproducibility assessment:

  • Test multiple antibody lots

  • Validate across different sample types and preparations

  • Implement positive and negative controls consistently

• Documentation requirements:

  • Record complete antibody information (clone, lot, vendor)

  • Document all validation experiments and results

  • Maintain validation data for each new lot

• Advanced validation approaches:

  • Orthogonal testing (correlate with mRNA expression)

  • Independent antibody testing (multiple antibodies against different epitopes)

  • Functional validation (correlate with known ADCY4 activities)

How should researchers interpret discrepancies between ADCY4 mRNA and protein expression data?

When facing mRNA-protein expression discrepancies:

• Common causes of discrepancies:

  • Post-transcriptional regulation (miRNAs, RNA-binding proteins)

  • Differences in protein stability and degradation rates

  • Technical variations in detection methods

  • Antibody specificity or sensitivity issues

• Investigative approaches:

  • Assess mRNA stability using actinomycin D chase experiments

  • Evaluate protein half-life with cycloheximide treatment

  • Screen for regulatory miRNAs targeting ADCY4

  • Test for post-translational modifications affecting protein stability

• Analytical strategies:

  • Use multiple antibodies targeting different epitopes

  • Employ absolute quantification methods when possible

  • Normalize data appropriately for each method

  • Consider time-course studies to capture dynamic regulation

• Biological interpretations:

  • Identify cell types where discrepancies are most pronounced

  • Investigate signaling pathways that might explain differential regulation

  • Consider disease-specific regulatory mechanisms

• Reporting recommendations:

  • Clearly distinguish between mRNA and protein measurements

  • Document all methodological details that might affect results

  • Discuss potential mechanisms for observed discrepancies